Toll-like receptor-4 signalling in the progression of non-alcoholic fatty liver disease induced by high-fat and high-fructose diet in mice

Clinical and Experimental Pharmacology and Physiology

Volumn 41, Issue 7, 2014, Pages 482-488

  Liu, Jing ^a   Zhuang, Zhen jie ^b   Bian, Dong xue ^a   Ma, Xiao jie ^a   Xun, Yun hao ^c   Yang, Wen jun ^b   Luo, Yan ^b   Liu, Yin lan ^b   Jia, Ling ^a   Wang, Yan ^d   Zhu, Ming li ^c   Ye, De wei ^e   Zhou, Gang ^b   Lou, Guo qiang ^b   Shi, Jun ping ^b  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c Hangzhou Xixi Hospital   (China)

^d DALIAN UNIVERSITY   (China)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Mice; Non alcoholic fatty liver disease; Toll like receptor 4

Indexed keywords

ACTIVIN A; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; LIVER ENZYME; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; ACTIVIN; FAT INTAKE; FRUCTOSE; IRF3 PROTEIN, MOUSE; IRF7 PROTEIN, MOUSE; MYD88 PROTEIN, MOUSE; SUGAR INTAKE; TLR4 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET; DISEASE COURSE; FATTY LIVER; HEPATITIS; HIGH FRUCTOSE DIET; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIPID STORAGE; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER WEIGHT; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; FAT INTAKE; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; SUGAR INTAKE; TOXICITY;

ACTIVINS; ANIMALS; DIETARY FATS; DIETARY SUCROSE; FRUCTOSE; GENE EXPRESSION REGULATION; INTERFERON REGULATORY FACTOR-3; INTERFERON REGULATORY FACTOR-7; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903893149     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12241     Document Type: Article

References (29)

1. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 1221-31.
2. Hui JM, Kench JG, Chitturi S et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420-7.
3. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010; 51: 1820-32.
4. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: The emerging view. J. Hepatol. 2009; 51: 212-23.
5. Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008; 28: 13-24.
6. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J. Hepatol. 2009; 50: 204-10.
7. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2011; 8: 35-44.
8. de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin. Nutr. 2002; 21: 219-23.
9. Schaeffler A, Gross P, Buettner R et al. Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity. Immunology 2009; 126: 233-45.
10. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007; 47: 571-9.
11. Tsujimoto T, Kawaratani H, Kitazawa T et al. Immunotherapy for nonalcoholic steatohepatitis using the multiple cytokine production modulator Y-40138. World J. Gastroenterol. 2009; 15: 5533-40.
12. Seki E, De Minicis S, Osterreicher CH et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007; 13: 1324-32.
13. Li N, Cui X, Ge J et al. Activin A inhibits activities of lipopolysaccharide-activated macrophages via TLR4, not of TLR2. Biochem. Biophys. Res. Commun. 2013; 435: 222-8.
14. Kohli R, Kirby M, Xanthakos SA et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010; 52: 934-44.
15. Pappo I, Becovier H, Berry EM, Freund HR. Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat. J. Surg. Res. 1991; 51: 106-12.
16. Pappo I, Bercovier H, Berry EM, Haviv Y, Gallily R, Freund HR. Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide. J. Parenter. Enteral Nutr. 1992; 16: 529-32.
17. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass: Prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982; 82: 535-48.
18. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009; 50: 1094-104.
19. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 2010; 11: 373-84.
20. Li L, Chen L, Hu L et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011; 54: 1620-30.
21. Miura K, Kodama Y, Inokuchi S et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010; 139: 323-34. e7.
22. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 2008; 7: 496-507.
23. Su GL, Klein RD, Aminlari A et al. Kupffer cell activation by lipopolysaccharide in rats: Role for lipopolysaccharide binding protein and Toll-like receptor 4. Hepatology 2000; 31: 932-6.
24. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003; 37: 1043-55.
25. Shirai Y, Yoshiji H, Noguchi R et al. Cross talk between Toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2013; 28: 723-30.
26. Ebert S, Zeretzke M, Nau R, Michel U. Microglial cells and peritoneal macrophages release activin A upon stimulation with Toll-like receptor agonists. Neurosci. Lett. 2007; 413: 241-4.
27. Jones KL, Mansell A, Patella S et al. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc. Natl Acad. Sci. USA 2007; 104: 16239-44.
28. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
29. Nelson JE, Wilson L, Brunt EM et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011; 53: 448-57.